Anifrolumab
Sign in to saveAlso known as MDX-1333, MEDI-546
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
In the Vinony graph
Within Vinony's link graph, Anifrolumab is referenced by 486 other articles, and connects out to interferon type I, monoclonal antibody and interferon gamma.
It is catalogued under topics including Chemicals that do not have a ChemSpider ID assigned, Cutaneous lupus erythematosus and Drugs developed by AstraZeneca.
Its subject is documented across 9 Wikipedia language editions.
Wikidata facts
- Subclass of
- chemical compound
Show 2 more facts
- World Health Organisation international non-proprietary name
- anifrolumab
- subject has role
- monoclonal antibody
via Wikidata · CC0
~2 min read
Encyclopedic overview
9 sectionsContents
- Mechanism of Action
- Adverse effects
- History
- Society and culture
- Legal status
- Names
- References
- Further reading
- External links
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022. The U.S. Food and Drug Administration considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “Anifrolumab” article, available under the CC BY-SA 4.0 licence.